Axelar AB is a Swedish biotechnology company that focuses its activities on research related to the insulin-like growth factor-1 (IGF-1) receptor inhibitors and their applications in important human diseases, especially cancer.

Axelar’s overall objective is to develop innovative small-molecule compounds that inhibit the IGF-1 receptor for treatment of IGF-1 receptor-dependent diseases where a significant unmet medical need still exists.

Axelar aspires to move these compounds into the clinic and then to enter partnerships that ensures global development and commercialization.

Latest news

Press release November 13, 2009
Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA

Press release May 06, 2009
Successful Phase I/II Clinical Trial Results from Cancer Patients Treated with Anticancer Drug from Axelar AB

Press release June 17, 2008
Axelar initiates phase I/II clinical trial on cancer patients with the new anti-cancer drug AXL1717